Tumor hypoxia: A target for selective cancer therapy

Cancer Science

Volumn 94, Issue 12, 2003, Pages 1021-1028

  Kizaka Kondoh, Shinae ^a   Inoue, Masahiro ^b   Harada, Hiroshi ^a   Hiraoka, Masahiro ^a  

^a KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 BIS[[2 (DIMETHYLAMINO N OXIDE)ETHYL]AMINO] 5,8 DIHYDROXYANTHRAQUINONE; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 METHOXYESTRADIOL; 2 MORPHOLINO 8 PHENYLCHROMONE; 2,2 DIFLUORO N (2 HYDROXYETHYL) 3 (2 NITRO 1 IMIDAZOLYL)PROPIONAMIDE; 5 (1 AZIRIDINYL) 2,4 DINITROBENZAMIDE; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BLEOMYCIN; CALPHOSTIN C; CARBOGEN; DIPHENYLIODONIUM SALT; ERYTHROPOIETIN; GEFITINIB; HERBIMYCIN; HYBRID PROTEIN; MANNOHEPTULOSE; NICOTINAMIDE; NIMORAZOLE; RADIOSENSITIZING AGENT; RAPAMYCIN; SANAZOLE; THYMIDINE KINASE; TIRAPAZAMINE; TOP3 PROTEIN; TRASTUZUMAB; TX 1845; TX 1846; UNCLASSIFIED DRUG; UNINDEXED DRUG; WORTMANNIN;

CANCER CHEMOTHERAPY; CANCER SURVIVAL; CANCER THERAPY; CELL HYPOXIA; CLINICAL TRIAL; CYTOTOXICITY; DRUG MECHANISM; DRUG METABOLISM; GENE DELIVERY SYSTEM; HUMAN; IONIZING RADIATION; MALIGNANT NEOPLASTIC DISEASE; MITOSIS INHIBITION; MOLECULAR DYNAMICS; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REVIEW; SENSITIVITY AND SPECIFICITY; SOLID TUMOR; TARGET CELL; TISSUE INJURY; TISSUE OXYGENATION; TUMOR CELL; TUMOR VASCULARIZATION;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL HYPOXIA; GENE EXPRESSION; GENE THERAPY; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; NEOPLASMS; RECOMBINANT FUSION PROTEINS;

EID: 0347029631     PISSN: 13479032     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2003.tb01395.x     Document Type: Review

References (50)

1. Vaupel P, Kallinowski F, Okunieff P. Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res 1989; 49: 6449-65.
2. Harris AL. Hypoxia - a key regulator factor in tumor growth. Nat Rev Cancer 2002; 2: 38-47.
3. Hockel M, Vaupel P. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst 2001; 93: 266-76.
4. Lu H, Forbes RA, Verma. A. Hypoxia-inducible factor 1 activation by aerobic glycolysis implicates the Warburg effect in carcinogenesis. J Biol Chem 2002; 277: 23111-5.
5. Brunelle JK, Chandel NS. Oxygen deprivation induced cell death: an update. Apoptosis 2002; 7: 475-82.
6. McClintock DS, Santore MT, Lee VY, Brunelle J, Budinger GR, Zong WX, Thompson CB, Hay N, Chandel NS. Bcl-2 family members and functional electron transport chain regulate oxygen deprivation induced cell death. Mol Cell Biol 2002; 22: 94-104.
7. Schuler M, Green DR. Mechanisms of p53-dependent apoptosis. Biochem Soc Trans 2001; 29: 684-8.
8. 2 homeostasis by hypoxia-inducible factor 1. Annu Rev Cell Dev Biol 1999; 15: 551-78.
9. Ivan M, Kondo K, Yang H, Kim W, Valiando J, Ohh M, Salic A, Asara JM, Lane WS, Kaelin WG. HIF-1α targeted for VHL-mediated destruction by proline hydroxylation: implications for oxygen sensing. Science 2001; 292: 464-8.
10. Epstein AC, Gleadle JM, McNeill LA, Hewitson KS, O'Rourke J, Mole DR, Mukherji M, Metzen E, Wilson MI, Dhanda A, Tian YM, Masson N, Hamilton DL, Jaakkola P, Barstead R, Hodgkin J, Maxwell PH, Pugh CW, Schofield CJ, Ratcliffe PJ. C. elegans EGL-9 and mammalian homologs define a family of deoxygenases that regulate HIF by prolyl hydroxylation. Cell 2001; 107: 43-54.
11. Lando D, Peet DJ, Whelan DA, Gorman JJ, Whitelaw ML. Asparagine hydroxylation of the HIF transactivation domain: a hypoxic switch. Science 2002; 295: 858-61.
12. Mahon PC, Hirota K, Semenza GL. FIH-1: a novel protein that interact with HIF-1α and VHL to mediate repression of HIF-1 transcriptional activity. Genes Dev 2001; 15: 2675-86.
13. Laughner E, Taghavi P, Chiles K, Mahon PC, Semenza GL. HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1α (HIF-1α) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol Cell Biol 2001; 21: 3995-4004.
14. Ravi R, Mookerjee B, Bhujwalla ZM, Sutter CH, Artemov D, Zeng Q, Dillehay LE, Madan A, Semenza GL, Bedi A. Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1α Genes Dev 2000; 14: 34-44.
15. Jain RK. Tumor angiogenesis and accessibility: role of vascular endothelial growth factor. Semin Oncol 2002; 29 (6 Suppl 16): 3-9.
16. Mirnezami AH, Campbell SJ, Darley M, Primrose JN, Johnson PW, Blaydes JP. Hdm2 recruits a hypoxia-sensitive corepressor to negatively regulate p53-dependent transcription. Curr Biol 2003; 13: 234-9.
17. Dong Z, Wang JZ, Yu F, Venkatachalam MA. Apoptosis-resistance of hypoxic cells: multiple factors involved and a role for IAP-2. Am J Pathol 2003; 163: 663-71.
18. Schmedtje JF Jr, Ji YS, Liu WL, DuBois RN, Runge MS. Hypoxia induces cyclooxygenase-2 via the NF-kB p65 transcription factor in human vascular endothelial cells. J Biol Chem 1997; 272: 601-8.
19. Murphy BJ, Andrews GK, Bittel D, Discher DJ, McCue J, Green CJ, Yanovsky M, Giaccia A, Sutherland RM, Laderoute KR, Webster KA. Activation of metallothionein gene expression by hypoxia involves metal response elements and metal transcription factor-1. Cancer Res 1999; 59: 315-22.
20. Yan SF, Lu J, Zoo YS, Soh-Won J, Cohen DM, Buttrick PM, Cooper DR, Steinberg SF, Mackman N, Pinsky DJ, Stern DM. Hypoxia-associated induction of early growth response-1 gene expression. J Biol Chem 1999; 274: 15030-40.
21. Durand RE. The influence of microenvironmental factors during cancer therapy. In Vivo 1994; 8: 691-702.
22. Teicher BA. Hypoxia and drug resistance. Cancer Metastasis Rev 1994; 13: 139-68.
23. Hockel M, Schlenger K, Aral B, Mitze, M, Schaffer U, Vaupel P. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res 1996; 56: 4509-15.
24. Pugh CW, Ratcliffe PJ. Regulation of angiogenesis by hypoxia: role of the HIF system. Nat Med 2003; 9: 677-84.
25. Beavon IR. The E-cadherin-catenin complex in tumour metastasis: structure, function and regulation. Eur J Cancer 2000; 36: 1607-20.
26. Yoon DY, Buchler P, Saarikoski ST, Hines OJ, Reber HA, Hankinson O. Identification of genes differentially induced by hypoxia in pancreatic cancer cells. Biochem Biophys Res Commun 2001; 288: 882-6.
27. Pennacchietti S, Michieli P, Galluzzo M, Mazzone M, Giordano S, Comoglio PM. Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell 2003; 3: 347-61.
28. O'Rourke JF, Dachs GU, Gleadle JM, Maxwell PH, Pugh CW, Stratford IJ, Wood SM, Ratchliffe PJ. Hypoxia response elements. Oncol Res 1997; 9: 327-32.
29. Harmey JH, Dimitriadis E, Kay E, Redmond HP, Bouchier-Hayes D. Regulation of macrophage production of vascular endothelial growth factor (VEGF) by hypoxia and transforming growth factor β-1. Ann Surg Oncol 1998; 5: 271-8.
30. Graeber TG, Osmanian C, Jacks T, Housman DE, Koch CJ, Lowe SW, Giaccia AJ. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 1996; 379: 88-91.
31. Kasai S, Nagasawa H, Yamashita M, Masui M, Kuwasaka H, Oshodani T, Uto Y, Inomata T, Oka S, Inayama S, Hori H. New antimetastatic hypoxic cell radiosensitizers: design, synthesis, and biological activities of 2-nitroimidazole-acetamide, TX-1877, and its analogues. Bioorg Med Chem 2001; 9: 453-64.
32. Brown JM. Exploiting the hypoxic cancer cell: mechanisms and therapeutic strategies. Mol Med Today 2000; 6: 157-62.
33. Wouters BG, Weppler SA, Koritzinsky M, Landuyt W, Nuyts S, Theys J, Chin RK, Lambin P. Hypoxia as a target for combined modality treatments. Eur J Cancer 2002; 38: 240-57.
34. Greco O, Patterson AV, Dachs GU. Can gene therapy overcome the problem of hypoxia in radiotherapy? J Radiat Res 2000; 41: 201-12.
35. Chen J, Zhao S, Nakada K, Kuge Y, Tamaki N, Okada F, Wang J, Shindo M, Higashino F, Takeda K, Asaka M, Katoh H, Sugiyama T, Hosokawa M, Kobayashi M. Dominant-negative hypoxia-inducible factor-1a reduces tumorigenicity of pancreatic cancer cells through the suppression of glucose metabolism. Am J Pathol 2003; 162: 1283-91.
36. Mabjeesh NJ, Escuin D, LaVallee TM, Pribluda VS, Swartz GM, Johnson MS, Willard MT, Zhong H, Simons JW, Giannakakou P. 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF. Cancer Cell 2003; 3: 363-75.
37. Peters KB, Brown JM. Tirapazamine: a hypoxia-activated topoisomerase II poison. Cancer Res 2002; 62: 5248-53.
38. Patterson LH, McKeown SR. AQ4N: a new approach to hypoxia-activated cancer chemotherapy. Br J Cancer 2000; 83: 1589-93.
39. Binley K, Askham Z, Martin L, Spearman H, Day D, Kingsman S, Naylor S. Hypoxia-mediated tumour targeting. Gene Ther 2003; 10: 540-9.
40. Post DE, van Meir EG. A novel hypoxia-inducible factor (HIF) activated oncolytic adenovirus for cancer therapy. Oncogene 2003; 22: 2065-72.
41. Hernandez-Alcoceba R, Pihalja M, Qian D, Clarke MF. New oncolytic adenoviruses with hypoxia- and estrogen receptor-regulated replication. Hum Gene Ther 2002; 13: 1737-50.
42. Jain RK, Forbes NS. Can engineered bacteria help control cancer? Proc Natl Acad Sci USA 2001; 98: 14748-50.
43. Liu SC, Minton NP, Giaccia AJ, Brown JM. Anticancer efficacy of systemically delivered anaerobic bacteria as gene therapy vectors targeting tumor hypoxia/necrosis. Gene Ther 2002; 9: 291-6.
44. Yazawa K, Fujimori M, Nakamura T, Sasaki T, Amano J, Kano Y, Taniguchi S. Bifidobacterium longum as a delivery system for gene therapy of chemically induced rat mammary tumors. Breast Cancer Res Treat 2001; 66: 165-70.
45. Dang LH, Bettegowda C, Huso DL, Kinzler KW, Vogelstein B. Combination bacteriolytic therapy for the treatment of experimental tumors. Proc Natl Acad Sci USA 2001; 98: 15155-60.
46. Griffiths L, Binley K, Iqball S, Kan O, Maxwell P, Ratcliffe P, Lewis C, Harris A, Kingsman S, Naylor S. The macrophage-a novel system to deliver gene therapy to pathological hypoxia. Gene Ther 2000; 7: 255-62.
47. Harada H, Hiraoka M, Kizaka-Kondoh S. Antitumor effect of TAT-oxygen-dependent degradation-caspase-3 fusion protein specifically stabilized and activated in hypoxic tumor cells. Cancer Res 2002; 62: 2013-8.
48. Becker-Hapak M, McAllister SS, Dowdy SF. TAT-mediated protein transduction into mammalian cells. Methods 2001; 24: 247-56.
49. Schwarze SR, Ho A, Vocero-Akbani A, Dowdy SF. In vivo protein transduction: delivery of a biologically active protein into the mouse. Science 1999; 285: 1569-72.
50. Asoh S, Ohsawa I, Mori T, Katsura. K, Hiraide T, Katayama Y, Kimura M, Ozaki D, Yamagata K, Ohta S. Protection against ischemic brain injury by protein therapeutics. Proc Natl Acad Sci USA 2002; 99: 17107-12.